Skip to content

Drug interactions

Eliglustat + Lorlatinib

Severity: Major

Eliglustat and Lorlatinib: major interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Eliglustat is metabolized by CYP2D6 and CYP3A4, and lorlatinib may lower its exposure. This can lead to loss of efficacy in Gaucher disease.

What this interaction means in plain words

Eliglustat and Lorlatinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Eliglustat belongs to Miscellaneous; Lorlatinib belongs to Oncology.

Evidence level: Moderate

Why it happens

Lorlatinib induces CYP3A4, increasing eliglustat metabolism.

What to do

Eliglustat labeling advises against use with strong CYP3A inducers, so choose an alternative or avoid the combination. If it cannot be avoided, monitor clinical response closely.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Eliglustat and Lorlatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Eliglustat with Lorlatinib?

MediHelp rates the interaction as major. Eliglustat and Lorlatinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Eliglustat is metabolized by CYP2D6 and CYP3A4, and lorlatinib may lower its exposure. This can lead to loss of efficacy in Gaucher disease.

How serious is the interaction between Eliglustat and Lorlatinib?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Eliglustat labeling advises against use with strong CYP3A inducers, so choose an alternative or avoid the combination. If it cannot be avoided, monitor clinical response closely.

What other medicines interact with Lorlatinib?

MediHelp also lists interactions of Lorlatinib with, for example, Amobarbital, Apalutamide, Butabarbital. The full list is on the Lorlatinib page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in